Impacts is a Phase II multi-center clinical trial evaluating the safety and effectiveness of intravenous A-001 (varespladib sodium) in preventing the development of acute chest syndrome in hospitalized sickle cell disease patients.
James Pennington, executive vice president and chief medical officer of Anthera, said: “We are pleased with the DSMB’s response and look forward to continuing the A-001 trial under our original protocol. Treatment options are limited for this important patient population and we believe a drug that provides an opportunity for early intervention would help address a significant unmet medical need.”